Dr. Baz on Selinexor in Multiple Myeloma

Rachid Baz, MD, associate member, head of the Myeloma Section at Moffitt Cancer Center, discusses the potential use of selinexor (KPT-330) in patients with multiple myeloma.

Physicians at Moffitt Cancer Center have had selinexor in the clinical trial setting for the past 4 to 5 years—since the first phase I trial in hematologic malignancies, says Baz. The agent has demonstrated activity in patients who have penta-refractory disease, though it may be worthwhile to study in combination, explains Baz.

If it was used in combination, it could be given on a once-weekly schedule. Investigational combinations include those with bortezomib (Velcade), carfilzomib (Kyprolis), and lenalidomide (Revlimid), all of which have demonstrated high response rates so far, states Baz. Teasing out where those combinations will fall will be important, explains Baz. It is unlikely that selinexor will be used in combination with dexamethasone.

In July 2018, Karyopharm Therapeutics, the manufacturer of the XPO1 inhibitor, submitted a new drug application to the FDA for the treatment of patients with penta-refractory multiple myeloma.